Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5718 PK, Bioavailability, and Food Effect Study
NCT02963116Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atuliflapon in coronary artery disease (CAD) (5 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from time zero to infinity at 48 hours, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration at 48 hours and 1 more. Started Dec 2016; status: completed.
02
Drugs
atuliflapon
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT02963116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963116.